The Drug in Phase 3 Trials That Doctors Are Already Excit...

Already excited sits at the center of this dementia and brain health question.

The drug generating the most excitement among dementia researchers and clinicians in recent Phase 3 trials is lecanemab (marketed as Leqembi), developed by Eisai and Biogen, though several other candidates — including donanemab from Eli Lilly — have also shown meaningful results in late-stage testing. What sets these apart from decades of failed Alzheimer’s drugs is that they have demonstrated statistically significant slowing of cognitive decline in large-scale trials, not just clearing amyloid plaques from the brain but actually translating that biological change into a measurable clinical benefit. For patients and families who have watched one promising drug after another collapse in Phase 3, this represents a genuine shift in the treatment landscape. The reason doctors are particularly energized is not that these drugs cure Alzheimer’s — they do not — but that they validate the amyloid hypothesis enough to suggest we are finally intervening in the right biological pathway.

Lecanemab’s confirmatory Phase 3 trial, known as Clarity AD, enrolled nearly 1,800 participants with early-stage Alzheimer’s and showed a 27 percent slowing of cognitive decline over 18 months compared to placebo. Donanemab’s TRAILBLAZER-ALZ 2 trial reported similar results, with some subgroups showing even more pronounced benefits. This article covers what these drugs actually do, who they work best for, the serious risks involved, what the approval and access landscape looks like, and why the next wave of Phase 3 candidates could be even more important than what we have now. It is worth noting upfront that the field is moving quickly, and some details about regulatory status, pricing, and ongoing trial results may have changed since the most recent publicly available data. Where specific figures are cited below, they reflect information available as of recent reports and should be verified against current sources.

Why Are Doctors Excited About These Phase 3 Alzheimer’s Drugs When So Many Have Failed Before?
How These Drugs Work and What Their Limitations Are
The Safety Profile That Keeps Coming Up in Every Conversation
Who Should Consider These Treatments and What the Tradeoffs Look Like
The Next Wave of Phase 3 Candidates and Why They Matter
What Combination Therapy Could Look Like
Where This Is Headed and What Families Should Watch For
Conclusion
Frequently Asked Questions

Why Are Doctors Excited About These Phase 3 Alzheimer’s Drugs When So Many Have Failed Before?

The history of Alzheimer’s drug development is littered with expensive failures. Between 2003 and 2019, more than 100 drugs targeting various aspects of the disease failed in clinical trials, many of them in Phase 3, which is the final and most costly stage of testing before a drug can seek regulatory approval. The failure rate for Alzheimer’s drugs during this period was estimated at over 99 percent — a staggering figure even by the high-risk standards of neuroscience drug development. Most of these drugs targeted amyloid-beta plaques, the sticky protein deposits that accumulate in the brains of Alzheimer’s patients, and the repeated failures led many researchers to question whether amyloid was even the right target. What changed with lecanemab and donanemab is that these drugs were tested in patients much earlier in the disease process and were designed to bind more selectively to specific forms of amyloid. Earlier drugs like aducanumab (Aduhelm) cleared amyloid effectively but produced inconsistent or ambiguous clinical results, leading to one of the most controversial FDA approvals in recent memory.

Lecanemab, by contrast, targets soluble amyloid protofibrils — the toxic, early-stage clumps that many scientists believe do the most damage to neurons — rather than just the mature plaques that had been the focus of older therapies. Donanemab takes a different but complementary approach, targeting a modified form of amyloid called N3pG that is primarily found in established plaques. The clinical difference matters. In the Clarity AD trial, participants receiving lecanemab showed a 0.45-point difference on the CDR-SB scale (a standard measure of dementia severity) compared to placebo. That may sound small in the abstract, but it translates to roughly five to seven additional months of preserved cognitive function over the trial period, according to some clinical interpretations. For a disease where the current standard of care offers only modest symptomatic relief, that represents the first disease-modifying therapy with credible evidence behind it.

Why Are Doctors Excited About These Phase 3 Alzheimer's Drugs When So Many Have Failed Before?

How These Drugs Work and What Their Limitations Are

Both lecanemab and donanemab are monoclonal antibodies — lab-engineered proteins that are delivered by intravenous infusion and designed to bind to amyloid-beta in the brain, flagging it for removal by the immune system. Lecanemab is typically administered every two weeks, while donanemab was tested on a monthly infusion schedule, which some patients and caregivers view as a practical advantage. Both drugs achieved substantial amyloid clearance in trial participants, with many patients reaching amyloid-negative status on PET imaging within 12 to 18 months of treatment. However, clearing amyloid from the brain is not the same as stopping the disease. Alzheimer’s involves multiple pathological processes, including tau protein tangles, neuroinflammation, and synaptic loss, and amyloid removal alone does not reverse damage that has already occurred. The clinical benefits seen in trials, while statistically significant, are modest in absolute terms.

Some patients and caregivers may not notice a perceptible difference in daily function, and the drugs have not been shown to help people with moderate or advanced Alzheimer’s. If a patient has already progressed beyond the early symptomatic stage, these treatments are unlikely to provide meaningful benefit based on current evidence. There is also a critical biological caveat. Patients who carry two copies of the APOE4 gene — the strongest genetic risk factor for Alzheimer’s — appear to be at significantly higher risk of serious side effects from anti-amyloid therapies, particularly a condition called ARIA (amyloid-related imaging abnormalities). In the donanemab trial, three deaths were linked to ARIA in APOE4 homozygotes, a finding that has prompted considerable debate about how aggressively these patients should be treated. Genetic testing before starting therapy has become a standard recommendation, though how to act on the results remains a point of clinical disagreement.

The Safety Profile That Keeps Coming Up in Every Conversation

ARIA is the defining safety concern for this entire class of drugs. It comes in two forms: ARIA-E, which involves fluid leakage (edema) in the brain, and ARIA-H, which involves microhemorrhages or superficial siderosis (iron deposits from small bleeds). In the Clarity AD trial, approximately 13 percent of lecanemab-treated patients developed ARIA-E, and about 17 percent showed ARIA-H on MRI monitoring. Most cases were mild and resolved without symptoms, but a small percentage of patients experienced headaches, confusion, dizziness, or visual disturbances, and in rare cases, ARIA led to serious complications. The practical implication is that patients receiving these drugs require regular MRI monitoring — typically before treatment, after the first few infusions, and periodically throughout therapy.

This adds logistical burden and cost, and it means that the drugs are not suitable for patients who cannot undergo frequent MRI scans, such as those with certain types of implanted medical devices. For community neurologists who may see only a handful of Alzheimer’s patients per year, managing these monitoring protocols represents a significant shift in practice. The donanemab data raised additional red flags. In the TRAILBLAZER-ALZ 2 trial, ARIA-E occurred in roughly 24 percent of patients in the treatment group, a notably higher rate than lecanemab, although direct cross-trial comparisons are imperfect because of differences in study design and patient populations. The deaths in the donanemab trial, particularly among APOE4 homozygotes, added urgency to the conversation about patient selection. The reality is that for patients at highest genetic risk of Alzheimer’s, these drugs also carry the highest risk of serious side effects — a cruel irony that the field is still working to address.

Who Should Consider These Treatments and What the Tradeoffs Look Like

As of recent reports, these anti-amyloid therapies are indicated for patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease dementia who have confirmed amyloid pathology. Confirming amyloid status requires either a PET scan or a cerebrospinal fluid test, both of which add cost and complexity to the diagnostic process. Blood-based biomarker tests that can detect amyloid and tau with reasonable accuracy are in development and may eventually simplify this step, but their availability and insurance coverage vary. The tradeoff calculus is different for every patient and family. On one hand, a treatment that slows decline by roughly 25 to 35 percent over 18 months could mean additional months of independence, preserved ability to recognize loved ones, or more time to manage financial and legal affairs while the patient can still participate in those decisions.

On the other hand, the treatment requires biweekly or monthly infusions at a specialized center, regular MRI monitoring, and carries a risk of brain swelling or bleeding that — while usually manageable — can in rare cases be life-threatening. Cost is another major factor. Lecanemab’s list price was set at approximately $26,500 per year when it received traditional FDA approval, though what patients actually pay depends heavily on insurance coverage, and Medicare coverage decisions have significant implications for access. Donanemab’s pricing, if and when it receives approval in various markets, adds another variable. For families already stretched thin by the costs of dementia care — which historically have averaged well over $300,000 over the course of the disease according to Alzheimer’s Association estimates — the financial dimension is not a footnote. It is a central part of the decision.

The Next Wave of Phase 3 Candidates and Why They Matter

While lecanemab and donanemab have received the most public attention, the pipeline of Alzheimer’s drugs in Phase 3 or late-stage trials extends beyond amyloid-targeting antibodies. Several candidates are pursuing entirely different mechanisms, and their success or failure will shape the field for the next decade. Among the most closely watched are drugs targeting tau protein, neuroinflammation, and synaptic protection. Anti-tau therapies represent a particularly important frontier because tau tangles correlate more closely with cognitive decline than amyloid plaques do. However, early results have been mixed. Semorinemab, an anti-tau antibody developed by Genentech, failed to meet its primary endpoint in a Phase 2 trial, though it showed some signals on secondary measures.

Other tau-targeting approaches, including antisense oligonucleotides that reduce tau production at the genetic level, are still in earlier stages of testing. The warning here is that tau biology is at least as complex as amyloid biology, and the same pattern of initial promise followed by Phase 3 disappointment could easily repeat. Neuroinflammation is another area generating Phase 3 interest. The brain’s immune cells, called microglia, play a dual role in Alzheimer’s — they can clear toxic proteins but also drive damaging inflammation. Drugs that modulate microglial activity, such as those targeting the TREM2 receptor, are being studied as potential standalone treatments or combination partners for anti-amyloid therapies. The limitation is that we do not yet fully understand how to tune the brain’s immune response — suppressing neuroinflammation too broadly could impair the brain’s ability to handle infections or clear cellular debris.

The Next Wave of Phase 3 Candidates and Why They Matter

What Combination Therapy Could Look Like

The most likely future of Alzheimer’s treatment is not a single drug but a combination regimen, much like the multi-drug approaches used in cancer and HIV. A patient might receive an anti-amyloid antibody to clear existing plaques, an anti-tau therapy to prevent tangle formation, and a neuroprotective agent to preserve synaptic function — all simultaneously or in sequence.

Eli Lilly and Eisai have both discussed combination strategies publicly, and some early-stage trials are already testing dual-mechanism approaches. For example, combining amyloid clearance with GLP-1 receptor agonists — a class of drugs originally developed for diabetes that have shown neuroprotective properties in preclinical studies — is an area of active investigation. The practical challenge is that each additional drug adds cost, infusion time, monitoring requirements, and potential for drug-drug interactions, so the evidence bar for combinations will need to be high.

Where This Is Headed and What Families Should Watch For

The most transformative development on the horizon may not be a new drug at all but the maturation of blood-based diagnostic tests. If a simple blood draw can reliably detect Alzheimer’s pathology 10 or 15 years before symptoms appear, it opens the door to preventive treatment — intervening with anti-amyloid or anti-tau therapies when the brain still has most of its neurons intact, rather than after significant damage has occurred. Several large prevention trials using this approach are in planning or early enrollment stages.

For families navigating this landscape today, the honest message from the clinical community is one of cautious optimism. We have, for the first time, drugs that demonstrably slow the progression of Alzheimer’s disease, and the pipeline behind them is deeper and more diverse than at any point in history. But these are not cures, they come with real risks, they require significant infrastructure to deliver safely, and their benefits are measured in months of preserved function rather than disease reversal. Staying informed about trial results, regulatory decisions, and emerging biomarker tests — through sources like the Alzheimer’s Association, ClinicalTrials.gov, and your neurologist — is the most actionable step most families can take right now.

Conclusion

The excitement among doctors about Phase 3 Alzheimer’s drugs is grounded in something real: after decades of failure, lecanemab and donanemab have demonstrated that clearing amyloid from the brain can slow cognitive decline in early-stage patients. This is not a theoretical finding or a biomarker-only result — it is a measurable difference in how quickly patients lose the ability to manage daily life. At the same time, the limitations are equally real. These drugs work only in early disease, carry meaningful risks including brain swelling and bleeding, require extensive monitoring, and cost tens of thousands of dollars per year.

They are a beginning, not an ending. What matters most going forward is that this generation of drugs has opened the door to rational combination therapy, earlier intervention, and a much more sophisticated understanding of who will benefit from treatment and who will not. Families should have frank conversations with their neurologists about whether current therapies are appropriate for their specific situation, including genetic risk factors, disease stage, and the practical realities of infusion-based treatment. The era of disease-modifying Alzheimer’s therapy has genuinely arrived, but navigating it wisely requires the same thing it always has — accurate information, realistic expectations, and a care team you trust.

Frequently Asked Questions

Are these new Alzheimer’s drugs a cure?

No. Lecanemab and donanemab slow the rate of cognitive decline but do not stop or reverse Alzheimer’s disease. In clinical trials, treated patients still declined — just more slowly than those on placebo, by roughly 25 to 35 percent over 18 months.

Who is eligible for treatment with anti-amyloid therapies?

As of recent guidance, candidates are generally patients with mild cognitive impairment or mild Alzheimer’s dementia who have confirmed amyloid pathology via PET scan or cerebrospinal fluid testing. Patients with moderate or advanced Alzheimer’s were not included in the pivotal trials and are generally not considered eligible.

What is ARIA and how dangerous is it?

ARIA (amyloid-related imaging abnormalities) refers to brain swelling or microbleeds that can occur with anti-amyloid drugs. Most cases are mild and asymptomatic, detected only on MRI monitoring. However, serious cases can cause confusion, headaches, or neurological symptoms, and rare fatalities have occurred, particularly in patients carrying two copies of the APOE4 gene.

Should APOE4 carriers avoid these treatments?

This is a nuanced clinical decision. APOE4 homozygotes (two copies) are at significantly higher risk for ARIA and were the subgroup where deaths occurred in trials. Many clinicians recommend genetic testing before starting treatment and careful risk-benefit discussions with APOE4 carriers. It does not automatically disqualify someone, but it changes the risk calculus substantially.

How much do these treatments cost?

Lecanemab’s list price was approximately $26,500 per year at the time of its traditional FDA approval. Actual out-of-pocket costs depend on insurance coverage, including Medicare decisions, which have been evolving. The total cost of treatment also includes regular MRI monitoring and infusion center fees, which can add several thousand dollars annually.

Are there non-amyloid drugs in Phase 3 trials?

Yes. Several drugs targeting tau protein, neuroinflammation, and other mechanisms are in late-stage development. There is also growing interest in repurposed drugs like GLP-1 receptor agonists that may have neuroprotective effects. The field is moving toward combination therapies that address multiple aspects of Alzheimer’s pathology simultaneously.

For more, see NIH MedlinePlus — dementia.

The Drug in Phase 3 Trials That Doctors Are Already Excited About

Table of Contents